Xcovery Partners with EVERSANA to Expand Commercial Launch of ALK-Positive NSCLC Drug Ensacove
核心洞察
Xcovery Holdings (搜索) has partnered with EVERSANA (搜索) to support the U.S. commercial launch of Ensacove (ensartinib), a next-generation ALK (搜索) inhibitor for adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (搜索).
The drug is indicated for treatment-naïve patients who have not previously received an ALK (搜索) inhibitor and is now available in the United States following FDA approval.
EVERSANA (搜索) will provide comprehensive end-to-end commercialization services including market access, commercial and medical teams to broaden patient access across the U.S.
Xcovery Holdings (搜索), Inc. has announced a strategic partnership with EVERSANA (搜索) to support and expand the U.S. commercial launch of ENSACOVE (ensartinib), a novel therapy for adult patients with anaplastic lymphoma kinase (搜索) (ALK (搜索))-positive locally advanced or metastatic non-small cell lung cancer (搜索) (NSCLC (搜索)). The agreement, announced on April 27, 2026, positions EVERSANA as the comprehensive commercialization partner for this next-generation ALK inhibitor.
Drug Profile and Indication
Ensacove (ensartinib) is a next-generation ALK (搜索) inhibitor jointly developed by Xcovery and Betta Pharmaceuticals, Co., Ltd. The drug is indicated for the treatment of adult patients with ALK-positive locally advanced or metastatic NSCLC (搜索) as detected by an FDA-approved test who have not previously received an ALK inhibitor. The therapy is now available in the United States for these patients.
Partnership Structure
Under the agreement, EVERSANA (搜索) will provide comprehensive end-to-end commercialization services for Xcovery, including agency of record, market access, commercial and medical teams to support the company's strategy to make Ensacove available to more patients across the U.S.
"The approval of Ensartinib was a major milestone in our mission to advance precision oncology," said Giovanni Selvaggi, M.D., Chief Medical Officer of Xcovery Holdings (搜索), Inc. "As we expand the U.S. launch of ENSACOVE, we are focused on ensuring that patients and providers have the support they need. EVERSANA (搜索) brings highly experienced, scalable commercialization capabilities, and we're pleased to partner with them to broaden patient access."
Gregory Skalicky, President of EVERSANA (搜索), emphasized the partnership's potential impact: "EVERSANA was built to help companies just like Xcovery implement more impactful commercial strategies, which will allow more patients to benefit from therapies like Ensartinib."
Safety Profile and Monitoring Requirements
Ensacove carries several important safety considerations requiring careful monitoring. The drug can cause interstitial lung disease (搜索) (ILD)/pneumonitis (搜索), which occurred in 5% of patients, including 1.3% Grade 3 and 0.4% Grade 4 cases. Healthcare providers must monitor patients for new or worsening symptoms and permanently discontinue the drug if ILD/pneumonitis develops.
Hepatotoxicity (搜索) represents another significant concern, with 59% of patients experiencing increased alanine aminotransferase (ALT), including 5% Grade 3 cases. Increased aspartate aminotransferase (AST) occurred in 58% of patients, including 1.8% Grade 3. The prescribing information requires liver function test monitoring at baseline and every two weeks during the first treatment cycle, then monthly or as clinically indicated.
Dermatologic and Other Adverse Events
Dermatologic adverse reactions occurred in 80% of patients, including Grade 3 reactions in 14% of patients. Rash was reported in 72% of patients, with Grade 3 severity in 12% of cases. Pruritus affected 32% of patients, including 2.4% Grade 3 cases. There was one Grade 3 case (0.2%) of drug reaction with eosinophilia and systemic symptoms (DRESS).
Additional monitoring requirements include regular heart rate assessment due to bradycardia occurring in 6% of patients, periodic serum glucose monitoring as hyperglycemia affected 44% of patients, and creatine phosphokinase monitoring since increased CPK occurred in 43% of patients with available laboratory data.
Contraindications and Drug Interactions
Ensacove is contraindicated in patients who have experienced severe hypersensitivity reactions to the drug, FD&C Yellow No. 5 (tartrazine), or any of its components. The drug contains FD&C Yellow No. 5, which may cause allergic-type reactions including bronchial asthma in susceptible individuals.
Healthcare providers should avoid concomitant use of P-gp inhibitors and moderate or strong CYP3A inhibitors or inducers. The drug should be avoided in patients with severe hepatic impairment, defined as total bilirubin greater than three times the upper limit of normal and any AST elevation.
Reproductive Safety
Ensacove can cause fetal harm, requiring patients to use effective contraception during treatment and for one week after the last dose. Women should not breastfeed during treatment and for one week following the final dose.
The most common adverse reactions with an incidence of 20% or greater included rash, musculoskeletal pain, constipation, pruritus, cough, nausea, edema, vomiting, fatigue, and pyrexia.